肿瘤细胞治疗研究
英文原题：Advances in preclinical and clinical studies of oncolytic virus combination therapy.
溶瘤病毒代表了一类独特的病毒，它们能够选择性地感染并摧毁肿瘤细胞，同时不影响正常细胞。
溶瘤病毒是一类独特的病毒，能够选择性感染并破坏肿瘤细胞，同时不损伤正常细胞。尽管具有潜力，溶瘤病毒作为单一疗法仍面临若干挑战。因此，溶瘤病毒与其他治疗方式的联合已成为突出的研究焦点。本文总结了溶瘤病毒的杀肿瘤机制，探讨了其与放疗、化疗、免疫检查点抑制剂、CAR-T和CAR-NK疗法的整合，并概述了相关临床试验。通过综合这些进展，本研究旨在为溶瘤病毒联合疗法的临床转化提供有价值的见解。
Oncolytic viruses represent a distinct class of viruses that selectively infect and destroy tumor cells while sparing normal cells. Despite their potential, oncolytic viruses encounter several challenges as standalone therapies. Consequently, the combination of oncolytic viruses with other therapeutic modalities has emerged as a prominent research focus. This paper summarizes the tumor-killing mechanisms of oncolytic viruses, explores their integration with radiotherapy, chemotherapy, immune checkpoint inhibitors, CAR-T, and CAR-NK therapies, and provides an overview of related clinical trials. By synthesizing these advancements, this study seeks to offer valuable insights for the clinical translation of oncolytic virus combination therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
